Author
Judd E. Hollander
Other affiliations: Thomas Jefferson University Hospital, Hospital of the University of Pennsylvania, Rutgers University ...read more
Bio: Judd E. Hollander is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Emergency department & Chest pain. The author has an hindex of 75, co-authored 442 publications receiving 25246 citations. Previous affiliations of Judd E. Hollander include Thomas Jefferson University Hospital & Hospital of the University of Pennsylvania.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide is useful in establishing or excluding the diagnosis of congestive heart failure in patients with acute dyspnea.
Abstract: Background B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension. Methods We conducted a prospective study of 1586 patients who came to the emergency department with acute dyspnea and whose B-type natriuretic peptide was measured with a bedside assay. The clinical diagnosis of congestive heart failure was adjudicated by two independent cardiologists, who were blinded to the results of the B-type natriuretic peptide assay. Results The final diagnosis was dyspnea due to congestive heart failure in 744 patients (47 percent), dyspnea due to noncardiac causes in 72 patients with a history of left ventricular dysfunction (5 percent), and no finding of congestive heart failure in 770 patients (49 percent). B-type natriuretic peptide levels by themselves were more accurate than any historical or physical findings or laboratory values in identifying congestive heart failure as the cause of dyspnea. The diagnostic accuracy of B-type natriuretic peptide at a cutoff ...
3,130 citations
••
TL;DR: Telemedicine for Covid-19’s payment and regulatory structures, licensing, credentialing, and implementation take time to work through, but health systems that have a...
Abstract: Virtually Perfect? Telemedicine for Covid-19 Telemedicine’s payment and regulatory structures, licensing, credentialing, and implementation take time to work through, but health systems that have a...
2,130 citations
••
Duke University1, Cleveland Clinic2, University of Alberta3, Stavanger University Hospital4, Pierre-and-Marie-Curie University5, Veterans Health Administration6, University of California, San Francisco7, University of Glasgow8, Université de Montréal9, University of Gothenburg10, University of North Carolina at Chapel Hill11, Charité12, University of Oslo13, Rabin Medical Center14, Johnson & Johnson15, Emory University16, Universidade Federal do Rio Grande do Sul17, Pontifical Catholic University of Chile18, Linköping University19, MetroHealth20, University of California, Los Angeles21, Janssen Pharmaceutica22, University of Maryland, Baltimore23, University of Florida24, University of Pennsylvania25, Dalhousie University26, Ford Motor Company27, Monash University28, Vilnius University29, University of Washington30, Mexican Social Security Institute31, University of Brescia32, Seoul National University33, Mayo Clinic34, Wrocław Medical University35, Mahidol University36, University of Otago37, University of Groningen38, Thomas Jefferson University39
TL;DR: In this article, Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies.
Abstract: A b s t r ac t Background Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. Methods We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. Results Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P = 0.03) and 24 hours (68.2% vs. 66.1%, P = 0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, −0.7 percentage points; 95% confidence interval [CI], −2.1 to 0.7; P = 0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, −0.4 percentage points; 95% CI, −1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P = 0.11). Conclusions Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.)
1,046 citations
••
TL;DR: Cognitive therapy was effective in preventing suicide attempts for adults who recently attempted suicide and reported significantly less hopelessness than the usual care group at 6 months and 18 months.
Abstract: ContextSuicide attempts constitute a major risk factor for completed suicide,
yet few interventions specifically designed to prevent suicide attempts have
been evaluated.ObjectiveTo determine the effectiveness of a 10-session cognitive therapy intervention
designed to prevent repeat suicide attempts in adults who recently attempted
suicide.Design, Setting, and ParticipantsRandomized controlled trial of adults (N = 120) who attempted
suicide and were evaluated at a hospital emergency department within 48 hours
of the attempt. Potential participants (N = 350) were consecutively
recruited from October 1999 to September 2002; 66 refused to participate and
164 were ineligible. Participants were followed up for 18 months.InterventionCognitive therapy or enhanced usual care with tracking and referral
services.Main Outcome MeasuresIncidence of repeat suicide attempts and number of days until a repeat
suicide attempt. Suicide ideation (dichotomized), hopelessness, and depression
severity at 1, 3, 6, 12, and 18 months.ResultsFrom baseline to the 18-month assessment, 13 participants (24.1%) in
the cognitive therapy group and 23 participants (41.6%) in the usual care
group made at least 1 subsequent suicide attempt (asymptotic z score, 1.97; P = .049). Using the Kaplan-Meier
method, the estimated 18-month reattempt-free probability in the cognitive
therapy group was 0.76 (95% confidence interval [CI], 0.62-0.85) and in the
usual care group was 0.58 (95% CI, 0.44-0.70). Participants in the cognitive
therapy group had a significantly lower reattempt rate (Wald χ21 = 3.9; P = .049)
and were 50% less likely to reattempt suicide than participants in the usual
care group (hazard ratio, 0.51; 95% CI, 0.26-0.997). The severity of self-reported
depression was significantly lower for the cognitive therapy group than for
the usual care group at 6 months (P= .02), 12
months (P = .009), and 18 months (P = .046). The cognitive therapy group reported
significantly less hopelessness than the usual care group at 6 months (P = .045). There were no significant differences
between groups based on rates of suicide ideation at any assessment point.ConclusionCognitive therapy was effective in preventing suicide attempts for adults
who recently attempted suicide.
822 citations
01 Jan 2005
TL;DR: In this article, the authors evaluated the effectiveness of a 10-session cognitive therapy inter-vention designed to prevent repeated suicide attempts in a randomized controlled trial of 120 individuals who attempted suicide and were evaluated at a hospital emergency department within 48 hours of the attempt.
Abstract: Context Suicide attempts constitute a major risk factor for completed suicide, yet fewinterventions specifically designed to prevent suicide attempts have been evaluated.Objective To determine the effectiveness of a 10-session cognitive therapy inter-ventiondesignedtopreventrepeatsuicideattemptsinadultswhorecentlyattemptedsuicide.Design,Setting,andParticipants Randomizedcontrolledtrialofadults(N=120)whoattemptedsuicideandwereevaluatedatahospitalemergencydepartmentwithin48 hours of the attempt. Potential participants (N=350) were consecutively recruitedfrom October 1999 to September 2002; 66 refused to participate and 164 were in-eligible. Participants were followed up for 18 months.Intervention Cognitive therapy or enhanced usual care with tracking and referralservices.MainOutcomeMeasures Incidenceofrepeatsuicideattemptsandnumberofdaysuntil a repeat suicide attempt. Suicide ideation (dichotomized), hopelessness, and de-pression severity at 1, 3, 6, 12, and 18 months.Results From baseline to the 18-month assessment, 13 participants (24.1%) in thecognitive therapy group and 23 participants (41.6%) in the usual care group made atleast1subsequentsuicideattempt(asymptotic
790 citations
Cited by
More filters
••
TL;DR: In those older than age 50, systolic blood pressure of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP, and hypertension will be controlled only if patients are motivated to stay on their treatment plan.
Abstract: The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Like its predecessors, the purpose is to provide an evidence-based approach to the prevention and management of hypertension. The key messages of this report are these: in those older than age 50, systolic blood pressure (BP) of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP; beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals (systolic BP 120-139 mm Hg or diastolic BP 80-89 mm Hg) require health-promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high-risk conditions that are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount.
14,975 citations
••
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
13,400 citations
••
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
11,386 citations
••
TL;DR: ACCF/AHAIAI: angiotensin-converting enzyme inhibitor as discussed by the authors, angio-catabolizing enzyme inhibitor inhibitor inhibitor (ACS inhibitor) is a drug that is used to prevent atrial fibrillation.
Abstract: ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation
7,489 citations
••
TL;DR: The current guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation are based on the findings of the ESC Task Force on 12 March 2015.
Abstract: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
6,866 citations